The DOI matches its Crossref record; 242 of the 242 references it cites were found in a registry or an index.
Rational Design of Multitarget-Directed Ligands: Strategies and Emerging Paradigms
Open accessAbstract
Due to the complexity of multifactorial diseases, single-target drugs do not always exhibit satisfactory efficacy. Recently, increasing evidence indicates that simultaneous modulation of multiple targets may improve both therapeutic safety and efficacy, compared with single-target drugs. However, few multitarget drugs are on market or in clinical trials, despite the best efforts of medicinal chemists. This article discusses the systematic establishment of target combination, lead generation, and optimization of multitarget-directed ligands (MTDLs). Moreover, we analyze some MTDLs research cases for several complex diseases in recent years and the physicochemical properties of 117 clinical multitarget drugs, with the aim to reveal the trends and insights of the potential use of MTDLs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Palladium-Catalyzed Cross-Coupling Reactions of Organoboron Compounds
Miyaura, N., & Suzuki, A. (1995) · Chemical Reviews · doi:10.1021/cr00039a007 · Cited by 12,817
Immunity, Inflammation, and Cancer
Grivennikov, S. I., Greten, F. R., & Karin, M. (2010) · Cell · doi:10.1016/j.cell.2010.01.025 · Cited by 10,755
Whiteford, H. A., Degenhardt, L., Rehm, J., Baxter, A. J., Ferrari, A. J., Erskine, H. E., Charlson, F. J., Norman, R. E., Flaxman, A. D., Johns, N., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(13)61611-6 · Cited by 6,006
Network pharmacology: the next paradigm in drug discovery
Hopkins, A. L. (2008) · Nature Chemical Biology · doi:10.1038/nchembio.118 · Cited by 4,622
Grundy, S. M., Benjamin, I. J., Burke, G. L., Chait, A., Eckel, R. H., Howard, B. V., Mitch, W., Smith, S. C., & Sowers, J. R. (1999) · Circulation · doi:10.1161/01.cir.100.10.1134 · Cited by 2,698
Vousden, K. H., & Lane, D. P. (2007) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2147 · Cited by 2,272
Strategies and challenges for the next generation of antibody–drug conjugates
Beck, A., Goetsch, L., Dumontet, C., & Corvaïa, N. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.268 · Cited by 2,271
Targeting HER2-Positive Breast Cancer with Trastuzumab-DM1, an Antibody–Cytotoxic Drug Conjugate
Lewis Phillips, G. D., Li, G., Dugger, D. L., Crocker, L. M., Parsons, K. L., Mai, E., Blättler, W. A., Lambert, J. M., Chari, R. V. J., Lutz, R. J., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-1776 · Cited by 1,676
Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders
Falkenberg, K. J., & Johnstone, R. W. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4360 · Cited by 1,564
Recent advances in Sonogashira reactions
Chinchilla, R., & Nájera, C. (2011) · Chemical Society Reviews · doi:10.1039/c1cs15071e · Cited by 1,541
Induced protein degradation: an emerging drug discovery paradigm
Lai, A. C., & Crews, C. M. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.211 · Cited by 1,486
Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug
Capdeville, R., Buchdunger, E., Zimmermann, J., & Matter, A. (2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd839 · Cited by 1,389
Diabetes, Hypertension, and Cardiovascular Disease: An Update
Sowers, J. R., Epstein, M., & Frohlich, E. D. (2001) · Hypertension · doi:10.1161/01.hyp.37.4.1053 · Cited by 1,332
Click Chemistry: 1,2,3‐Triazoles as Pharmacophores
Agalave, S. G., Maujan, S. R., & Pore, V. S. (2011) · Chemistry – An Asian Journal · doi:10.1002/asia.201100432 · Cited by 1,305
O'Hare, T., Shakespeare, W. C., Zhu, X., Eide, C. A., Rivera, V. M., Wang, F., Adrian, L. T., Zhou, T., Huang, W.-S., Xu, Q., et al. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.09.028 · Cited by 1,259
Designed Multiple Ligands. An Emerging Drug Discovery Paradigm
Morphy, R., & Rankovic, Z. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm058225d · Cited by 1,209
Hypertension and Antihypertensive Therapy as Risk Factors for Type 2 Diabetes Mellitus
Gress, T. W., Nieto, F. J., Shahar, E., Wofford, M. R., & Brancati, F. L. (2000) · New England Journal of Medicine · doi:10.1056/nejm200003303421301 · Cited by 1,202
Roth, B. L., Sheffler, D. J., & Kroeze, W. K. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1346 · Cited by 1,155
Multi-target-Directed Ligands To Combat Neurodegenerative Diseases
Cavalli, A., Bolognesi, M. L., Minarini, A., Rosini, M., Tumiatti, V., Recanatini, M., & Melchiorre, C. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm7009364 · Cited by 1,152
Polypharmacology: Challenges and Opportunities in Drug Discovery: Miniperspective
Anighoro, A., Bajorath, J., & Rastelli, G. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm5006463 · Cited by 1,131
Targeting the cancer epigenome for therapy
Jones, P. A., Issa, J.-P. J., & Baylin, S. (2016) · Nature Reviews Genetics · doi:10.1038/nrg.2016.93 · Cited by 1,128
Multi-target therapeutics: when the whole is greater than the sum of the parts
Zimmermann, G. R., Lehár, J., & Keith, C. T. (2007) · Drug Discovery Today · doi:10.1016/j.drudis.2006.11.008 · Cited by 1,105
Benson, S. C., Pershadsingh, H. A., Ho, C. I., Chittiboyina, A., Desai, P., Pravenec, M., Qi, N., Wang, J., Avery, M. A., & Kurtz, T. W. (2004) · Hypertension · doi:10.1161/01.hyp.0000123072.34629.57 · Cited by 1,073
Konecny, G. E., Pegram, M. D., Venkatesan, N., Finn, R., Yang, G., Rahmeh, M., Untch, M., Rusnak, D. W., Spehar, G., Mullin, R. J., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-1182 · Cited by 914
Targeting the EGFR signaling pathway in cancer therapy
Seshacharyulu, P., Ponnusamy, M. P., Haridas, D., Jain, M., Ganti, A. K., & Batra, S. K. (2012) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2011.648617 · Cited by 913
(2006) · PubMed · Cited by 906
Crystal structure of the human angiotensin-converting enzyme–lisinopril complex
Natesh, R., Schwager, S. L. U., Sturrock, E. D., & Acharya, K. R. (2003) · Nature · doi:10.1038/nature01370 · Cited by 888
Dynamics of the 2001 UK Foot and Mouth Epidemic: Stochastic Dispersal in a Heterogeneous Landscape
Keeling, M. J., Woolhouse, M. E. J., Shaw, D. J., Matthews, L., Chase-Topping, M., Haydon, D. T., Cornell, S. J., Kappey, J., Wilesmith, J., & Grenfell, B. T. (2001) · Science · doi:10.1126/science.1065973 · Cited by 880
Assessing Atropisomer Axial Chirality in Drug Discovery and Development
LaPlante, S. R., Fader, L. D., Fandrick, K. R., Fandrick, D. R., Hucke, O., Kemper, R., Miller, S. P. F., & Edwards, P. J. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm200584g · Cited by 861
Oxidative damage in the central nervous system: protection by melatonin
Reiter, R. J. (1998) · Progress in Neurobiology · doi:10.1016/s0301-0082(98)00052-5 · Cited by 838
Kim, D., Wang, L., Beconi, M., Eiermann, G. J., Fisher, M. H., He, H., Hickey, G. J., Kowalchick, J. E., Leiting, B., Lyons, K., et al. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm0493156 · Cited by 822
The Effect of Prescribed Daily Dose Frequency on Patient Medication Compliance
Eisen, S. A. (1990) · Archives of Internal Medicine · doi:10.1001/archinte.150.9.1881 · Cited by 817
Antibody-Drug Conjugates in Cancer Therapy
Sievers, E. L., & Senter, P. D. (2013) · Annual Review of Medicine · doi:10.1146/annurev-med-050311-201823 · Cited by 770
Senter, P. D., & Sievers, E. L. (2012) · Nature Biotechnology · doi:10.1038/nbt.2289 · Cited by 763
From magic bullets to designed multiple ligands
Morphy, R., Kay, C., & Rankovic, Z. (2004) · Drug Discovery Today · doi:10.1016/s1359-6446(04)03163-0 · Cited by 729
A perspective on multi‐target drug discovery and design for complex diseases
Ramsay, R. R., Popovic‐Nikolic, M. R., Nikolic, K., Uliassi, E., & Bolognesi, M. L. (2018) · Clinical and Translational Medicine · doi:10.1186/s40169-017-0181-2 · Cited by 718
Paracetamol: New Vistas of an Old Drug
Bertolini, A., Ferrari, A., Ottani, A., Guerzoni, S., Tacchi, R., & Leone, S. (2006) · CNS Drug Reviews · doi:10.1111/j.1527-3458.2006.00250.x · Cited by 674
Genetic identification of brain cell types underlying schizophrenia
Major Depressive Disorder Working Group of the Psychiatric Genomics Consortium, Skene, N. G., Bryois, J., Bakken, T. E., Breen, G., Crowley, J. J., Gaspar, H. A., Giusti-Rodriguez, P., Hodge, R. D., Miller, J. A., et al. (2018) · Nature Genetics · doi:10.1038/s41588-018-0129-5 · Cited by 651
Seven Year Itch: Pan-Assay Interference Compounds (PAINS) in 2017—Utility and Limitations
Baell, J. B., & Nissink, J. W. M. (2018) · ACS Chemical Biology · doi:10.1021/acschembio.7b00903 · Cited by 648
Antibody−Drug Conjugates: Linking Cytotoxic Payloads to Monoclonal Antibodies
Ducry, L., & Stump, B. (2010) · Bioconjugate Chemistry · doi:10.1021/bc9002019 · Cited by 625
Savelieff, M. G., Nam, G., Kang, J., Lee, H. J., Lee, M., & Lim, M. H. (2019) · Chemical Reviews · doi:10.1021/acs.chemrev.8b00138 · Cited by 581
Angiotensin Receptors and Their Antagonists
Goodfriend, T. L., Elliott, M. E., & Catt, K. J. (1996) · New England Journal of Medicine · doi:10.1056/nejm199606203342507 · Cited by 558
Structural and Functional Basis of Cyclooxygenase Inhibition
Blobaum, A. L., & Marnett, L. J. (2007) · Journal of Medicinal Chemistry · doi:10.1021/jm0613166 · Cited by 550
Phenotypic screening in cancer drug discovery — past, present and future
Moffat, J. G., Rudolph, J., & Bailey, D. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4366 · Cited by 507
Liao, J. J.-L. (2007) · Journal of Medicinal Chemistry · doi:10.1021/jm0608107 · Cited by 507
Polypharmacology by Design: A Medicinal Chemist’s Perspective on Multitargeting Compounds
Proschak, E., Stark, H., & Merk, D. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b00760 · Cited by 498
Shifting from the single to the multitarget paradigm in drug discovery
Medina-Franco, J. L., Giulianotti, M. A., Welmaker, G. S., & Houghten, R. A. (2013) · Drug Discovery Today · doi:10.1016/j.drudis.2013.01.008 · Cited by 483
Structure of the D2 dopamine receptor bound to the atypical antipsychotic drug risperidone
Wang, S., Che, T., Levit, A., Shoichet, B. K., Wacker, D., & Roth, B. L. (2018) · Nature · doi:10.1038/nature25758 · Cited by 483
Can we rationally design promiscuous drugs?
HOPKINS, A., MASON, J., & OVERINGTON, J. (2006) · Current Opinion in Structural Biology · doi:10.1016/j.sbi.2006.01.013 · Cited by 469
From Single- to Multi-Target Drugs in Cancer Therapy: When Aspecificity Becomes an Advantage
Giordano, S., & Petrelli, A. (2008) · Current Medicinal Chemistry · doi:10.2174/092986708783503212 · Cited by 457
Martinez, A., Alonso, M., Castro, A., Pérez, C., & Moreno, F. J. (2002) · Journal of Medicinal Chemistry · doi:10.1021/jm011020u · Cited by 455
Martel-Pelletier, J., Lajeunesse, D., Reboul, P., & Pelletier, J.-P. (2003) · Annals of the Rheumatic Diseases · doi:10.1136/ard.62.6.501 · Cited by 439
The Stille Reaction, 38 Years Later
Cordovilla, C., Bartolomé, C., Martínez-Ilarduya, J. M., & Espinet, P. (2015) · ACS Catalysis · doi:10.1021/acscatal.5b00448 · Cited by 436
Small-molecule hydrophobic tagging–induced degradation of HaloTag fusion proteins
Neklesa, T. K., Tae, H. S., Schneekloth, A. R., Stulberg, M. J., Corson, T. W., Sundberg, T. B., Raina, K., Holley, S. A., & Crews, C. M. (2011) · Nature Chemical Biology · doi:10.1038/nchembio.597 · Cited by 429
Grant, S., Easley, C., & Kirkpatrick, P. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2227 · Cited by 412
Combination of antiangiogenesis with chemotherapy for more effective cancer treatment
Ma, J., & Waxman, D. J. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-0715 · Cited by 370
Estrogen receptor and breast cancer
Sommer, S., & Fuqua, S. A. W. (2001) · Seminars in Cancer Biology · doi:10.1006/scbi.2001.0389 · Cited by 355
Hopkins, A. L., Ren, J., Esnouf, R. M., Willcox, B. E., Jones, E. Y., Ross, C., Miyasaka, T., Walker, R. T., Tanaka, H., Stammers, D. K., et al. (1996) · Journal of Medicinal Chemistry · doi:10.1021/jm960056x · Cited by 346
How Beyond Rule of 5 Drugs and Clinical Candidates Bind to Their Targets
Doak, B. C., Zheng, J., Dobritzsch, D., & Kihlberg, J. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b01286 · Cited by 335
VanderMolen, K. M., McCulloch, W., Pearce, C. J., & Oberlies, N. H. (2011) · The Journal of Antibiotics · doi:10.1038/ja.2011.35 · Cited by 333
Dual or multi-targeting inhibitors: The next generation anticancer agents
Raghavendra, N. M., Pingili, D., Kadasi, S., Mettu, A., & Prasad, S. V. U. M. (2018) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2017.10.021 · Cited by 333
Synthesis and antifungal activity of 1,2,3-triazole containing fluconazole analogues
Aher, N. G., Pore, V. S., Mishra, N. N., Kumar, A., Shukla, P. K., Sharma, A., & Bhat, M. K. (2009) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2008.12.026 · Cited by 328
Dechant, K. L., & Clissold, S. P. (1991) · Drugs · doi:10.2165/00003495-199141020-00007 · Cited by 325
Multi-target approach for natural products in inflammation
Koeberle, A., & Werz, O. (2014) · Drug Discovery Today · doi:10.1016/j.drudis.2014.08.006 · Cited by 317
Natesh, R., Schwager, S. L. U., Evans, H. R., Sturrock, E. D., & Acharya, K. R. (2004) · Biochemistry · doi:10.1021/bi049480n · Cited by 295
Mendgen, T., Steuer, C., & Klein, C. D. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm201243p · Cited by 290
Koutsoukas, A., Simms, B., Kirchmair, J., Bond, P. J., Whitmore, A. V., Zimmer, S., Young, M. P., Jenkins, J. L., Glick, M., Glen, R. C., et al. (2011) · Journal of Proteomics · doi:10.1016/j.jprot.2011.05.011 · Cited by 287
The ups and downs of MEK kinase interactions
Hagemann, C., & Blank, J. L. (2001) · Cellular Signalling · doi:10.1016/s0898-6568(01)00220-0 · Cited by 275
Direct Nitric Oxide Detection in Aqueous Solution by Copper(II) Fluorescein Complexes
Lim, M. H., Wong, B. A., Pitcock, W. H., Mokshagundam, D., Baik, M.-H., & Lippard, S. J. (2006) · Journal of the American Chemical Society · doi:10.1021/ja064955e · Cited by 267
Hideshima, T., Richardson, P. G., & Anderson, K. C. (2011) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-0433 · Cited by 265
Westhoff, M. A., Serrels, B., Fincham, V. J., Frame, M. C., & Carragher, N. O. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.18.8113-8133.2004 · Cited by 263
Designing Multiple Ligands – Medicinal Chemistry Strategies and Challenges
Morphy, R., & Rankovic, Z. (2009) · Current Pharmaceutical Design · doi:10.2174/138161209787315594 · Cited by 262
Bolognesi, M. L., Cavalli, A., Valgimigli, L., Bartolini, M., Rosini, M., Andrisano, V., Recanatini, M., & Melchiorre, C. (2007) · Journal of Medicinal Chemistry · doi:10.1021/jm701225u · Cited by 260
Caffeine as a Protective Factor in Dementia and Alzheimer's Disease
Eskelinen, M. H., & Kivipelto, M. (2010) · Journal of Alzheimer's Disease · doi:10.3233/jad-2010-1404 · Cited by 259
Rodríguez-Franco, M. I., Fernández-Bachiller, M. I., Pérez, C., Hernández-Ledesma, B., & Bartolomé, B. (2006) · Journal of Medicinal Chemistry · doi:10.1021/jm050746d · Cited by 248
Resistance to Targeted Therapies: Refining Anticancer Therapy in the Era of Molecular Oncology
Ellis, L. M., & Hicklin, D. J. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1070 · Cited by 248
Poornima, P., Kumar, J. D., Zhao, Q., Blunder, M., & Efferth, T. (2016) · Pharmacological Research · doi:10.1016/j.phrs.2016.06.018 · Cited by 248
Sterling, J., Herzig, Y., Goren, T., Finkelstein, N., Lerner, D., Goldenberg, W., Miskolczi, I., Molnar, S., Rantal, F., Tamas, T., et al. (2002) · Journal of Medicinal Chemistry · doi:10.1021/jm020120c · Cited by 247
Designing multi-targeted agents: An emerging anticancer drug discovery paradigm
Fu, R.-G., Sun, Y., Sheng, W.-B., & Liao, D.-F. (2017) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2017.05.016 · Cited by 247
Targeting JAK kinase in solid tumors: emerging opportunities and challenges
Buchert, M., Burns, C. J., & Ernst, M. (2016) · Oncogene · doi:10.1038/onc.2015.150 · Cited by 243
Somu, R. V., Boshoff, H., Qiao, C., Bennett, E. M., Barry, C. E., & Aldrich, C. C. (2006) · Journal of Medicinal Chemistry · doi:10.1021/jm051060o · Cited by 238
Structural Basis for an Unexpected Mode of SERM-Mediated ER Antagonism
Wu, Y.-L., Yang, X., Ren, Z., McDonnell, D. P., Norris, J. D., Willson, T. M., & Greene, G. L. (2005) · Molecular Cell · doi:10.1016/j.molcel.2005.04.014 · Cited by 232
Polypharmacology in a Single Drug: Multitarget Drugs
L. Bolognesi, M. (2013) · Current Medicinal Chemistry · doi:10.2174/0929867311320130004 · Cited by 230
Krause, M., Zhu, Y., Huhn, M., Schneider-Thoma, J., Bighelli, I., Nikolakopoulou, A., & Leucht, S. (2018) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-018-0869-3 · Cited by 230
Histone Deacetylase Inhibitors: Current Status and Overview of Recent Clinical Trials
Ma, X., Ezzeldin, H. H., & Diasio, R. B. (2009) · Drugs · doi:10.2165/11315680-000000000-00000 · Cited by 227
Belinostat: First Global Approval
Poole, R. M. (2014) · Drugs · doi:10.1007/s40265-014-0275-8 · Cited by 216
Lyketsos, C. G., Sheppard, J.-M. E., Steele, C. D., Kopunek, S., Steinberg, M., Baker, A. S., Brandt, J., & Rabins, P. V. (2000) · American Journal of Psychiatry · doi:10.1176/appi.ajp.157.10.1686 · Cited by 214
SRC: A Century of Science Brought to the Clinic
Aleshin, A., & Finn, R. S. (2010) · Neoplasia · doi:10.1593/neo.10328 · Cited by 211
Giacobini, E. (1998) · Neurochemistry International · doi:10.1016/s0197-0186(97)00124-1 · Cited by 209
Kalgutkar, A. S., Dalvie, D. K., Castagnoli, & Taylor, T. J. (2001) · Chemical Research in Toxicology · doi:10.1021/tx010073b · Cited by 209
Whiting, M., Tripp, J. C., Lin, Y.-C., Lindstrom, W., Olson, A. J., Elder, J. H., Sharpless, K. B., & Fokin, V. V. (2006) · Journal of Medicinal Chemistry · doi:10.1021/jm060754+ · Cited by 208
Wurz, R. P., Dellamaggiore, K., Dou, H., Javier, N., Lo, M.-C., McCarter, J. D., Mohl, D., Sastri, C., Lipford, J. R., & Cee, V. J. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b01781 · Cited by 205
Fragments, network biology and designing multiple ligands
Morphy, R., & Rankovic, Z. (2007) · Drug Discovery Today · doi:10.1016/j.drudis.2006.12.006 · Cited by 204
Millan, M. J. (2009) · Neurotherapeutics · doi:10.1016/j.nurt.2008.10.039 · Cited by 196
Esnouf, R. M., Ren, J., Hopkins, A. L., Ross, C. K., Jones, E. Y., Stammers, D. K., & Stuart, D. I. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.8.3984 · Cited by 195
The Physicochemical Challenges of Designing Multiple Ligands
Morphy, R., & Rankovic, Z. (2006) · Journal of Medicinal Chemistry · doi:10.1021/jm0603015 · Cited by 194
A review on tacrine-based scaffolds as multi-target drugs (MTDLs) for Alzheimer's disease
Sameem, B., Saeedi, M., Mahdavi, M., & Shafiee, A. (2017) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2016.10.060 · Cited by 194
Histamine H3 Receptor Antagonists Go to Clinics
Sander, K., Kottke, T., & Stark, H. (2008) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.31.2163 · Cited by 193
Modern Phenotypic Drug Discovery Is a Viable, Neoclassic Pharma Strategy
Lee, J. A., Uhlik, M. T., Moxham, C. M., Tomandl, D., & Sall, D. J. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm201649s · Cited by 192
Vascular Endothelial Growth Factor (VEGF) Receptors: Drugs and New Inhibitors
Musumeci, F., Radi, M., Brullo, C., & Schenone, S. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm301085w · Cited by 184
Lee, S., Zheng, X., Krishnamoorthy, J., Savelieff, M. G., Park, H. M., Brender, J. R., Kim, J. H., Derrick, J. S., Kochi, A., Lee, H. J., et al. (2014) · Journal of the American Chemical Society · doi:10.1021/ja409801p · Cited by 182
Safer anti-inflammatory therapy through dual COX-2/5-LOX inhibitors: A structure-based approach
P, J. J., Manju, S. L., Ethiraj, K. R., & Elias, G. (2018) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2018.06.003 · Cited by 182
Where Do Recent Small Molecule Clinical Development Candidates Come From?
Brown, D. G., & Boström, J. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b00675 · Cited by 176
Multitarget approach for natural products in inflammation
Jude, S., & Gopi, S. (2021) · Inflammation and Natural Products · doi:10.1016/b978-0-12-819218-4.00004-3 · Cited by 174
Savelieff, M. G., DeToma, A. S., Derrick, J. S., & Lim, M. H. (2014) · Accounts of Chemical Research · doi:10.1021/ar500152x · Cited by 172
A novel artemisinin–quinine hybrid with potent antimalarial activity
Walsh, J. J., Coughlan, D., Heneghan, N., Gaynor, C., & Bell, A. (2007) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2007.04.054 · Cited by 171
Rhodanine‐Based Tau Aggregation Inhibitors in Cell Models of Tauopathy
Bulic, B., Pickhardt, M., Khlistunova, I., Biernat, J., Mandelkow, E., Mandelkow�, E., & Waldmann, H. (2007) · Angewandte Chemie International Edition · doi:10.1002/anie.200704051 · Cited by 164
Blackburn, C., Gigstad, K. M., Hales, P., Garcia, K., Jones, M., Bruzzese, F. J., Barrett, C., Liu, J. X., Soucy, T. A., Sappal, D. S., et al. (2010) · Biochemical Journal · doi:10.1042/bj20100383 · Cited by 163
Guang, C., Phillips, R. D., Jiang, B., & Milani, F. (2012) · Archives of cardiovascular diseases · doi:10.1016/j.acvd.2012.02.010 · Cited by 161
Molecular Pathways: Molecular Basis for Sensitivity and Resistance to JAK Kinase Inhibitors
Meyer, S. C., & Levine, R. L. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0279 · Cited by 159
Contributions of Molecular Properties to Drug Promiscuity
Tarcsay, Á., & Keserű, G. M. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm301514n · Cited by 153
In-Silico Approaches to Multi-target Drug Discovery
Xiao, H., Shi, Z., Tan, C., Jiang, Y., Go, M., Low, B. C., & Chen, Y. (2010) · Pharmaceutical Research · doi:10.1007/s11095-010-0065-2 · Cited by 152
Comparative efficacy between venlafaxine and SSRIs: a pooled analysis of patients with depression
Stahl, S. M., Entsuah, R., & Rudolph, R. L. (2002) · Biological Psychiatry · doi:10.1016/s0006-3223(02)01425-7 · Cited by 151
Zimmermann, J., Buchdunger, E., Mett, H., Meyer, T., Lydon, N., & Traxler, P. M. (1996) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/0960-894x(96)00197-7 · Cited by 150
Zheng, H., Youdim, M. B. H., & Fridkin, M. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm900504c · Cited by 149
Aripiprazole, A Drug that Displays Partial Agonism and Functional Selectivity
Tuplin, E. W. N., & Holahan, M. R. (2017) · Current Neuropharmacology · doi:10.2174/1570159x15666170413115754 · Cited by 148
The Search for Potent, Small‐Molecule HDACIs in Cancer Treatment: A Decade After Vorinostat
Zagni, C., Floresta, G., Monciino, G., & Rescifina, A. (2017) · Medicinal Research Reviews · doi:10.1002/med.21437 · Cited by 147
Histamine H3Receptor as a Drug Discovery Target
Berlin, M. Y., Boyce, C. W., & Ruiz, M. D. L. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm100064d · Cited by 142
Novel paradigms for drug discovery: computational multitarget screening
Jenwitheesuk, E., HORST, J., Rivas, K. L., VanVoorhis, W. C., & Samudrala, R. (2008) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2007.11.007 · Cited by 141
Marco, J. L., Leon, R. M., Ríos, C. D. L., Samadi, A., Bartolini, M., Andrisano, V., Huertas, Ó., Barril, X., Luque, F. J., Rodríguez-Franco, M. I., et al. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm801292b · Cited by 137
Pan Assay Interference Compounds (PAINS) and Other Promiscuous Compounds in Antifungal Research
Pouliot, M., & Jeanmart, S. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b00361 · Cited by 132
Psychiatric symptoms associated with Alzheimer's disease
Mendez, M. F., Martin, R. J., Smyth, K. A., & Whitehouse, P. J. (1990) · Journal of Neuropsychiatry · doi:10.1176/jnp.2.1.28 · Cited by 129
The role of fragment-based and computational methods in polypharmacology
Bottegoni, G., Favia, A. D., Recanatini, M., & Cavalli, A. (2011) · Drug Discovery Today · doi:10.1016/j.drudis.2011.08.002 · Cited by 128
Jiang, X.-Y., Chen, T.-K., Zhou, J.-T., He, S.-Y., Yang, H.-Y., Chen, Y., Qu, W., Feng, F., & Sun, H.-P. (2018) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.7b00463 · Cited by 122
Self-citationQuinolines and Artemisinin: Chemistry, Biology and History
Bray, P. G., Ward, S. A., & O’Neill, P. M. (2005) · Springer eBooks · doi:10.1007/3-540-29088-5_1 · Cited by 122
Gandini, A., Bartolini, M., Tedesco, D., Martínez‐González, L., Roca, C., Campillo, N. E., Zaldívar-Díez, J., Pérez, C., Zuccheri, G., Miti, A., et al. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b00610 · Cited by 121
Role of endothelin in the cardiovascular system
Rodríguez‐Pascual, F., Busnadiego, Ó., Lagares, D., & Lamas, S. (2011) · Pharmacological Research · doi:10.1016/j.phrs.2011.01.014 · Cited by 116
Strategies for modern biomarker and drug development in oncology
Smith, A. D., Roda, D., & Yap, T. A. (2014) · Journal of Hematology & Oncology · doi:10.1186/s13045-014-0070-8 · Cited by 116
Kurtz, S. E., Eide, C. A., Kaempf, A. J., Khanna, V., Savage, S. L., Rofelty, A., English, I. A., Ho, H., Pandya, R., Bolosky, W. J., et al. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1703094114 · Cited by 115
Tacrine-resveratrol fused hybrids as multi-target-directed ligands against Alzheimer's disease
Jerábek, J., Uliassi, E., Guidotti, L., Korábečný, J., Soukup, O., Šepsová, V., Hrabinová, M., Kuča, K., Bartolini, M., Peña‐Altamira, E., et al. (2016) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2016.12.048 · Cited by 114
Zang, J., Liang, X., Huang, Y., Jia, Y., Li, X., Xu, W., Chou, C. J., & Zhang, Y. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b00384 · Cited by 114
Pindolol Augmentation of Antidepressant Response
Artigas, F., Adell, A., & Celada, P. (2006) · Current Drug Targets · doi:10.2174/138945006775515446 · Cited by 111
Huang, Y., Dong, G., Li, H., Liu, N., Zhang, W., & Sheng, C. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b00393 · Cited by 111
From Molecular Structure to Alzheimer Therapy
Giacobini, E. (1997) · The Japanese Journal of Pharmacology · doi:10.1254/jjp.74.225 · Cited by 110
Prati, F., Cavalli, A., & Bolognesi, M. (2016) · Molecules · doi:10.3390/molecules21040466 · Cited by 110
Sato, M., Kawakami, H., Motomura, T., Aramaki, H., Matsuda, T., Yamashita, M., Ito, Y., Matsuzaki, Y., Yamataka, K., Ikeda, S., et al. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm900460z · Cited by 109
Lu, C., Zhou, Q., Yan, J., Du, Z., Huang, L., & Li, X. (2013) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2013.01.039 · Cited by 107
Small Molecule Recognition of c-Src via the Imatinib-Binding Conformation
Dar, A. C., Lopez, M. S., & Shokat, K. M. (2008) · Chemistry & Biology · doi:10.1016/j.chembiol.2008.09.007 · Cited by 105
The use of multi-target drugs in the treatment of neurodegenerative diseases
der Schyf, C. J. V. (2011) · Expert Review of Clinical Pharmacology · doi:10.1586/ecp.11.13 · Cited by 103
Design and synthesis of fluconazole/bile acid conjugate using click reaction
Pore, V. S., Aher, N. G., Kumar, M., & Shukla, P. K. (2006) · Tetrahedron · doi:10.1016/j.tet.2006.09.021 · Cited by 103
Speck‐Planche, A., Kleandrova, V. V., Luan, F., & Cordeiro, M. N. D. S. (2012) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2012.05.071 · Cited by 102
Beck, M. W., Derrick, J. S., Kerr, R. A., Oh, S. B., Cho, W. J., Lee, S. J. C., Ji, Y., Han, J., Tehrani, Z. A., Suh, N., et al. (2016) · Nature Communications · doi:10.1038/ncomms13115 · Cited by 101
Multitarget drugs: the present and the future of cancer therapy
Petrelli, A., & Valabrega, G. (2009) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656560902781907 · Cited by 96
Braymer, J. J., Choi, J.-S., DeToma, A. S., Wang, C., Nam, K., Kampf, J. W., Ramamoorthy, A., & Lim, M. H. (2011) · Inorganic Chemistry · doi:10.1021/ic2012205 · Cited by 94
Melatonin attenuates amyloid beta25–35-induced apoptosis in mouse microglial BV2 cells
Jang, M.-H., Jung, S.-B., Lee, M., Kim, C., Oh, Y.-T., Kang, I., Kim, J., & Kim, E. (2005) · Neuroscience Letters · doi:10.1016/j.neulet.2005.01.003 · Cited by 92
Rationally Designed Dual Inhibitors of HIV Reverse Transcriptase and Integrase
Wang, Z., Bennett, E. M., Wilson, D. J., Salomon, C. E., & Vince, R. (2007) · Journal of Medicinal Chemistry · doi:10.1021/jm070512p · Cited by 92
Murugesan, N., Gu, Z., Fadnis, L., Tellew, J. E., Baska, R. A. F., Yang, Y., Beyer, S. M., Monshizadegan, H., Dickinson, K. E. J., Valentine, M. T., et al. (2004) · Journal of Medicinal Chemistry · doi:10.1021/jm049548x · Cited by 91
Melatonin improves learning and memory performances impaired by hyperhomocysteinemia in rats
Baydaş, G., Özer, M., Yaşar, A., Tuzcu, M., & Koz, S. T. (2005) · Brain Research · doi:10.1016/j.brainres.2005.04.011 · Cited by 90
Antimalarial Drug Therapy: The Role of Parasite Biology and Drug Resistance
Daily, J. P. (2006) · The Journal of Clinical Pharmacology · doi:10.1177/0091270006294276 · Cited by 87
Miller, M. L., Molinelli, E. J., Nair, J. S., Sheikh, T., Samy, R., Jing, X., He, Q., Korkut, A., Crago, A. M., Singer, S., et al. (2013) · Science Signaling · doi:10.1126/scisignal.2004014 · Cited by 86
Cesca, M., Bizzaro, F., Zucchetti, M., & Giavazzi, R. (2013) · Frontiers in Oncology · doi:10.3389/fonc.2013.00259 · Cited by 84
Woo, L. W. L., Jackson, T., Putey, A., Cozier, G. E., Leonard, P. M., Acharya, K. R., Chander, S. K., Purohit, A., Reed, M. J., & Potter, B. V. L. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm901705h · Cited by 83
Korábečný, J., Doležal, R., Cabelova, P., Horova, A., Hruba, E., Říčný, J., Sedláček, L., Nepovimová, E., Špilovská, K., Andrš, M., et al. (2014) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2014.05.066 · Cited by 82
Wong, E. H. F., Tarazi, F. I., & Shahid, M. (2010) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2010.02.001 · Cited by 82
Coleman, R. L., Sill, M. W., Thaker, P. H., Bender, D., Street, D. G., McGuire, W. P., Johnston, C. M., & Rotmensch, J. (2015) · Gynecologic Oncology · doi:10.1016/j.ygyno.2015.04.005 · Cited by 82
Palomo, V., Pérez, D. I., Roca, C., Anderson, C. J., Rodríguez‐Muela, N., Pérez, C., Morales-Garcia, J. A., Reyes, J. A., Campillo, N. E., Pérez‐Castillo, A., et al. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b00395 · Cited by 82
Serotonin Reuptake Inhibition: An Update on Current Research Strategies
Spinks, D., & Spinks, G. (2002) · Current Medicinal Chemistry · doi:10.2174/0929867024606795 · Cited by 81
Dual Aromatase−Steroid Sulfatase Inhibitors
Woo, L. W. L., Bubert, C., Sutcliffe, O. B., Smith, A., Chander, S. K., Mahon, M. F., Purohit, A., Reed, M. J., & Potter, B. V. L. (2007) · Journal of Medicinal Chemistry · doi:10.1021/jm061462b · Cited by 80
Chojnacki, J. E., Liu, K., Yan, X., Toldo, S. A., Selden, T. M., Estrada, M., Rodríguez-Franco, M. I., Halquist, M. S., Ye, D., & Zhang, S. (2014) · ACS Chemical Neuroscience · doi:10.1021/cn500081s · Cited by 80
Repurposing Medications for Treatment of Pulmonary Arterial Hypertension: What's Old Is New Again
Prins, K. W., Thenappan, T., Weir, Ε. K., Kalra, R., PRITZKER, M. R., & Archer, S. L. (2018) · Journal of the American Heart Association · doi:10.1161/jaha.118.011343 · Cited by 80
Ríos, C. D. L., Egea, J., Marco, J. L., Leon, R. M., Samadi, A., Iriepa, I., Moraleda, I., Galvez‐Ruano, E., García, A. G., López, M. G., et al. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm901902w · Cited by 79
Discovery of the First-in-Class Dual Histone Deacetylase–Proteasome Inhibitor
Bhatia, S., Krieger, V., Groll, M., Osko, J. D., Reßing, N., Ahlert, H., Borkhardt, A., Kurz, T., Christianson, D. W., Hauer, J., et al. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b01487 · Cited by 79
Gangjee, A., Zhao, Y., Lin, L., Raghavan, S., Roberts, E. G., Risinger, A. L., Hamel, E., & Mooberry, S. L. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm101010n · Cited by 74
A whole-animal platform to advance a clinical kinase inhibitor into new disease space
Sonoshita, M., Scopton, A. P., Ung, P. M. U., Murray, M. A., Silber, L., Maldonado, A. Y., Real, A. M., Schlessinger, A., Cagan, R. L., & Dar, A. C. (2018) · Nature Chemical Biology · doi:10.1038/nchembio.2556 · Cited by 73
Designed Multiple Ligands: Basic Research vs Clinical Outcomes
Costantino, L., & Barlocco, D. (2012) · Current Medicinal Chemistry · doi:10.2174/092986712801215883 · Cited by 72
Ryckmans, T., Balançon, L., Berton, O., Génicot, C., Lamberty, Y., Lallemand, B., Pasau, P., Pirlot, N., Quéré, L., & Talaga, P. E. (2002) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/s0960-894x(01)00727-2 · Cited by 70
Leopoldo, M., Lacivita, E., Giorgio, P. D., Fracasso, C., Guzzetti, S., Caccia, S., Contino, M., Colabufo, N. A., Berardi, F., & Perrone, R. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm800615e · Cited by 70
Derrick, J. S., Kerr, R. A., Nam, Y., Oh, S. B., Lee, H. J., Earnest, K. G., Suh, N., Peck, K. L., Özbil, M., Korshavn, K. J., et al. (2015) · Journal of the American Chemical Society · doi:10.1021/jacs.5b10043 · Cited by 70
Torok, S., Rezeli, M., Kelemen, O., Vegvari, A., Watanabe, K., Sugihara, Y., Tisza, A., Marton, T., Kovacs, I., Tovari, J., et al. (2017) · Theranostics · doi:10.7150/thno.16767 · Cited by 70
First Dual Aromatase-Steroid Sulfatase Inhibitors
Woo, L. W. L., Sutcliffe, O. B., Bubert, C., Grasso, A., Chander, S. K., Purohit, A., Reed, M. J., & Potter, B. V. L. (2003) · Journal of Medicinal Chemistry · doi:10.1021/jm034033b · Cited by 69
Combination of MEK and SRC inhibition suppresses melanoma cell growth and invasion
Ferguson, J., Arozarena, I., Ehrhardt, M., & Wellbrock, C. (2013) · Oncogene · doi:10.1038/onc.2012.25 · Cited by 68
He, S., Dong, G., Wu, S., Fang, K., Miao, Z., Wang, W., & Sheng, C. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b00664 · Cited by 68
Self-citationPei, Z., Li, X., Longenecker, K. L., von Geldern, T. W., Wiedeman, P. E., Lubben, T. H., Zinker, B. A., Stewart, K. D., Ballaron, S. J., Stashko, M. A., et al. (2006) · Journal of Medicinal Chemistry · doi:10.1021/jm051283e · Cited by 67
Khanfar, M. A., Hill, R. A., Kaddoumi, A., & Sayed, K. A. E. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm100941j · Cited by 65
Choy, E., Flamand, Y., Balasubramanian, S., Butrynski, J. E., Harmon, D. C., George, S., Cote, G. M., Wagner, A. J., Morgan, J. A., Sirisawad, M., et al. (2014) · Cancer · doi:10.1002/cncr.29175 · Cited by 64
Aromatase and Dual Aromatase‐Steroid Sulfatase Inhibitors from the Letrozole and Vorozole Templates
Wood, P. M., Woo, L. W. L., THOMAS, M. P., Mahon, M. F., Purohit, A., & Potter, B. V. L. (2011) · ChemMedChem · doi:10.1002/cmdc.201100145 · Cited by 64
Sheng, R., Tang, L., Jiang, L., Hong, L., Shi, Y., Zhou, N., & Hu, Y. (2015) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.5b00224 · Cited by 61
Smid, P., Coolen, H. K. A. C., Keizer, H. G., van Hes, R., de Moes, J., den Hartog, A. P., Stork, B., Plekkenpol, R. H., Niemann, L. C., Stroomer, C. N. J., et al. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm050148z · Cited by 60
H., X., Wang, R., Tan, C., Jiang, Y., Lu, T., Rao, H., Li, X., Go, M., Low, B. C., & Chen, Y. (2010) · Molecular Pharmaceutics · doi:10.1021/mp100179t · Cited by 60
Cui, Z., Li, X., Li, L., Zhang, B., Gao, C., Chen, Y., Tan, C., Liu, H., Xie, W., Yang, T., et al. (2015) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2015.12.011 · Cited by 60
Wang, Z., & Vince, R. (2008) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2008.02.007 · Cited by 59
Booth, L. A., Roberts, J. L., Sander, C., Lee, J., Kirkwood, J. M., Poklepovic, A. S., & Dent, P. (2017) · Oncotarget · doi:10.18632/oncotarget.14829 · Cited by 59
Advances in computational approaches in identifying synergistic drug combinations
Sheng, Z., Sun, Y., Yin, Z., Tang, K., & Cao, Z. (2017) · Briefings in Bioinformatics · doi:10.1093/bib/bbx047 · Cited by 58
Two‐Headed PROTAC: An Effective New Tool for Targeted Protein Degradation
Cyrus, K., Wehenkel, M., Choi, E., Swanson, H. I., & Kim, K. (2010) · ChemBioChem · doi:10.1002/cbic.201000222 · Cited by 57
Tao, L., Zhu, F., Xu, F., Chen, Z., Jiang, Y., & Chen, Y. (2015) · Pharmacological Research · doi:10.1016/j.phrs.2015.09.019 · Cited by 56
Leopoldo, M., Lacivita, E., Contino, M., Colabufo, N. A., Berardi, F., & Perrone, R. (2007) · Journal of Medicinal Chemistry · doi:10.1021/jm070487n · Cited by 56
Multi-target therapeutics for neuropsychiatric and neurodegenerative disorders
Bawa, P., Pradeep, P., Kumar, P., Choonara, Y. E., Modi, G., & Pillay, V. (2016) · Drug Discovery Today · doi:10.1016/j.drudis.2016.08.001 · Cited by 56
Casimiro‐Garcia, A., Filzen, G. F., Flynn, D. A., Bigge, C. F., Chen, J., Davis, J. A., Dudley, D. A., Edmunds, J. J., Esmaeil, N., Geyer, A. G., et al. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm200409s · Cited by 55
Novel indanone derivatives as MAO B/H3R dual-targeting ligands for treatment of Parkinson’s disease
Affini, A., Hagenow, S., Živković, A., Marco, J. L., & Stark, H. (2018) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2018.02.015 · Cited by 55
Laubli, H. P., Müller, P., D’Amico, L., Buchi, M., Kashyap, A. S., & Zippelius, A. (2018) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-018-2136-x · Cited by 53
Eleftheriadis, N., Poelman, H., Leus, N. G. J., Honrath, B., Neochoritis, C. G., Dolga, A. M., Dömling, A. S. S., & Dekker, F. J. (2016) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2016.07.010 · Cited by 51
Stacchiotti, S., Simeone, N., Vullo, S. L., Morosi, C., Greco, F. G., Gronchi, A., Barisella, M., Collini, P., Zaffaroni, N., Dagrada, G. P., et al. (2018) · European Journal of Cancer · doi:10.1016/j.ejca.2018.10.024 · Cited by 51
Gangjee, A., Zeng, Y., Ihnat, M. A., Warnke, L. A., Green, D. W., Kisliuk, R. L., & Lin, F. (2005) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2005.04.087 · Cited by 50
Zhang, X., Raghavan, S., Ihnat, M. A., Thorpe, J. E., Disch, B. C., Bastian, A., Bailey‐Downs, L. C., Dybdal‐Hargreaves, N. F., Rohena, C. C., Hamel, E., et al. (2014) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2014.04.049 · Cited by 50
Arfeen, M., Bhagat, S., Patel, R. V., Prasad, S., Roy, I., Chakraborti, A. K., & Bharatam, P. V. (2016) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2016.04.075 · Cited by 50
Narayanan, S., Harris, D. L., Maitra, R., & Runyon, S. P. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b00527 · Cited by 49
Selumetinib for the treatment of cancer
Ciombor, K. K., & Bekaii‐Saab, T. (2014) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2015.982275 · Cited by 47
Zhang, X., Raghavan, S., Ihnat, M. A., Hamel, E., Zammiello, C. L., Bastian, A., Mooberry, S. L., & Gangjee, A. (2015) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2015.03.061 · Cited by 44
Speck‐Planche, A., Kleandrova, V. V., Luan, F., & Cordeiro, M. N. D. S. (2012) · Combinatorial Chemistry & High Throughput Screening · doi:10.2174/138620712802650487 · Cited by 44
Patel, R. R., Sengupta, S., Kim, H. R., Klein–Szanto, A. J., Pyle, J. R., Zhu, F., Li, T., Ross, E. A., Oseni, S., Fargnoli, J., et al. (2010) · European Journal of Cancer · doi:10.1016/j.ejca.2010.02.018 · Cited by 44
Cited by
Albertini, C., Salerno, A., de Sena Murteira Pinheiro, P., & Bolognesi, M. L. (2021) · Medicinal Research Reviews · doi:10.1002/med.21699 · Cited by 179
Li, Y., Sang, S., Ren, W., Pei, Y., Bian, Y., Chen, Y., & Sun, H. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.113874 · Cited by 77
Self-citationHe, F., Chou, C. J., Scheiner, M., Poeta, E., Yuan Chen, N., Gunesch, S., Hoffmann, M., Sotriffer, C., Monti, B., Maurice, T., et al. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c01940 · Cited by 66
Jiang, X., Zhou, J., Wang, Y., Chen, L., Duan, Y., Huang, J., Liu, C., Chen, Y., Liu, W., Sun, H., et al. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112751 · Cited by 39
Self-citation(2022) · PubMed Central · Cited by 17
Metadata
- Authors
- Zhou, J., Jiang, X., He, S., Jiang, H., Feng, F., Liu, W., Qu, W., & Sun, H.
- Venue
- Journal of Medicinal Chemistry
- Publisher
- American Chemical Society (ACS)
- Published
- 2019-05-13
- Volume
- 62
- Issue
- 20
- Pages
- 8881-8914
- ISSN
- 0022-2623 (ISSN-L)
- 1520-4804
- OpenAlex
- W2945427404
- Cited by
- 281
- References
- 242
- FWCI
- 19.81
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.